AC Immune SA (ACIU) Dividend History

Company News

• AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

  AC Immune reported positive interim results from its Phase 2 trial of ACI-7104.056, an anti-alpha-synuclein active immunotherapy for Parkinson's disease. The company also highlighted progress in its early-stage pipeline and provided financial updates.

  GlobeNewswire Inc.
• AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

  AC Immune reported positive interim results from a Phase 2 trial of its anti-alpha-synuclein active immunotherapy candidate ACI-7104.056 for early Parkinson's disease. The treatment induced a strong antibody response and was well-tolerated, supporting further development.

  GlobeNewswire Inc.
• AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

  AC Immune, a biopharmaceutical company, announced upcoming presentations at the AD/PD™ 2025 conference, highlighting its pipeline of active immunotherapies for neurodegenerative diseases. The company will host an industry symposium featuring key opinion leaders and experts.

  GlobeNewswire Inc.
• AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update

  AC Immune reported positive clinical data for its pipeline of neurodegenerative disease therapies, including ACI-24.060, ACI-35.030, and ACI-7104.056. The company also signed a landmark $2.1 billion deal with Takeda for ACI-24.060 and received milestone payments from Janssen, ensuring funding into 2027.

  GlobeNewswire Inc.

  Featured Companies: JNJ
• AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome

  AC Immune reported interim safety data from the ABATE Phase 1b/2 trial of ACI-24.060 in individuals with Down syndrome. The investigational immunotherapy was generally safe and well-tolerated, with no serious adverse events or cases of amyloid-related imaging abnormalities observed. Based on these findings, AC Immune plans to open the high-dose cohort in the ABATE trial.

  GlobeNewswire Inc.